RNS Announcements

Change of registered office

19 April 2022

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces that it has changed its registered address to: First Floor, Zucchi Suite, Nostell Business Estate, Wakefield, WF4 1AB with immediate effect.

All formal notices and general correspondence should be sent to the new address.


For further information, please contact:

Probiotix Health plc Contact via Walbrook below
Stephen O’Hara, Chief Executive 
Peterhouse Capital Limited Tel: 020 7469 0930
Mark Anwyl (AQSE Corporate Adviser)  
Duncan Vasey (Broker)  
Walbrook PR Ltd Mob: 07876 741 001 or [email protected]
Anna Dunphy  


About ProBiotix Health plc

ProBiotix Health develops probiotics (live microbes that, when ingested, can alter the composition of the microbiome and improve human health) to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world.

ProBiotix Health’s cholesterol reducing probiotic, Lactobacillus plantarum ECGC13110402 (“LP-LDL®), is manufactured in pharmaceutical GMP-certified facilities and protected worldwide by in the region of 5 patent families, comprising 27 patents and pending patent applications, and 22 trademarks.